Hadassah

Collaboration Announced to Develop Hadassah Drug to Treat “Untreatable” NASH Liver Disease

Friday, Aug 5 2016

Hadasit, the Hadassah Medical Organization’s technology transfer company, has signed an agreement with BioLineRx Ltd. to develop a drug to treat non-alcoholic steatohepatitis (NASH), based on the pre-clinical work of Hadassah’s Prof. Rifaat Safadi, head of its Liver Unit. Currently, there are no Federal Drug Administration-approved treatments for NASH.

NASH is the progressive form of non-alcoholic fatty liver disease (NAFLD) and, in many cases, leads to cirrhosis of the liver and, ultimately, liver cancer. This “in-licensing agreement” represents a partnership between two companies with shared intentions, goals, and fields of interest. "Under the collaboration,” explains Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx,” Novartis will provide us with valuable professional advice and consultancy throughout the development process. This project fits our strategic focus on the immunology space, since it works through modulation of the immune system.”

The drug candidate, to be called BL-1210, offers a novel mechanism for controlling liver fibrosis, the scarring process that represents the liver's response to injury. When scar tissue builds up and takes over most of the liver, cirrhosis is the result. By modulating the immune system, the drug would reduce scarring and control the disease’s progression.

As Hadasit explains about the Hadassah Medical Center on its website, “The combination of practical experience, the ability to pinpoint medical needs, and cutting-edge research has yielded a huge potential for ideas, innovation, and developments in all aspects of medicine, including therapeutics, diagnostics, and medical devices. Founded in 1986, Hadasit has been investing in turning ideas into viable products and services for the benefit of humanity.”

Related Stories

alt_text

Monday, Dec 9 2019

First-Ever International Lifetime Achievement Award Goes to Hadassah Psychiatrist

The International Society for Affective Disorders (ISAD) has honored the Hadassah Medical Organization’s pioneering psychiatrist Prof. Bernard Lerer with its first-ever Lifetime Achievement Award.

READ MORE ›
alt_text

Monday, Dec 9 2019

Hadassah Leads Women’s Heart Disease Awareness Campaign Across Israel

From spearheading in-house education programs in Israel’s top-tier companies to displaying a giant inflatable heart in Tel Aviv’s Rabin Square...

READ MORE ›
alt_text

Tuesday, Nov 19 2019

Hadassah Hospital Staff Volunteer to Organize Circumcision Celebration for New Mom

There were tears of joy at Hadassah Hospital Mount Scopus recently as the staff mobilized to create a special circumcision ceremony for a new mother.

READ MORE ›
alt_text

Wednesday, Nov 13 2019

After Years of Unidentified Pain, Teenager Finds Relief at Hadassah

A very active, athletic 17-year-old girl arrived at Hadassah Hospital Ein Kerem complaining of pain in her stomach. She had no idea there was a massive growth in her abdomen that weighed more than six pounds.

READ MORE ›
SUPPORT HADASSAH HOSPITALS

Learn more about the Hadassah Medical Organization.

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More